Imidazo[1,2-a]quinazolines as novel, potent EGFR-TK inhibitors: Design, synthesis, bioactivity evaluation, and in silico studies-Reference-Cited by-同舟云学术

Imidazo[1,2-a]quinazolines as novel, potent EGFR-TK inhibitors: Design, synthesis, bioactivity evaluation, and in silico studies

Published:2023-04 Issue: Volume:133 Page:106383
ISSN:0045-2068
Container-title:Bioorganic Chemistry
language:en
Short-container-title:Bioorganic Chemistry

Author:

Hasanvand Zaman,Oghabi Bakhshaiesh Tayebeh,Peytam Fariba,Firoozpour Loghman,Hosseinzadeh Elaheh,Motahari Rasoul,Moghimi Setareh,Nazeri Elaheh,Toolabi Mahsa,Momeni Farhad,Bijanzadeh Hamidreza,Khalaj Ali,Baratte Blandine,Josselin Béatrice,Robert Thomas,Bach Stéphane,Esmaeili Rezvan,Foroumadi Alireza^ORCID

Funder

Tehran University of Medical Sciences and Health Services

Publisher

Elsevier BV

Subject

Organic Chemistry,Drug Discovery,Molecular Biology,Biochemistry

Reference54 articles.

1. WebMD, https://www.who.int/news-room/fact-sheets/detail/cancer.

2. Current molecular-targeted therapies in NSCLC and their mechanism of resistance;Schrank;Cancers,2018

3. An overview of cancer treatments;Anderson;Pharm. J.,2009

4. The Aurora kinase inhibitors in cancer research and therapy;Cicenas;J. Cancer Res. Clin. Oncol.,2016

5. Properties of FDA-approved small molecule protein kinase inhibitors: a update;Roskoski;Pharmacol. Res.,2021

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Structural Perspectives in the Development of Novel EGFR Inhibitors for the Treatment of NSCLC;Mini-Reviews in Medicinal Chemistry;2024-10

2. CADD Methods for Developing Novel Compounds Synthesized to Inhibit Tyrosine Kinase Receptors;Current Topics in Medicinal Chemistry;2024-08-07

3. Solvent-free Approaches towards the Synthesis of Therapeutically Important Heterocycles;Current Green Chemistry;2024-06

4. Design, Synthesis, and Biological Evaluation of Newly Synthesized Cinnamide-Fluorinated Containing Compounds as Bioactive Anticancer Agents;ACS Omega;2024-04-10

5. Recent Advances in Structural Optimization of Quinazoline-Based Protein Kinase Inhibitors for Cancer Therapy (2021–Present);Molecules;2024-02-16